Agricultural Activator Adjuvant Market set to hit worth US$ 6.6 billion at CAGR 4.9% during forecast period 2024 to 2034 ...

A djuvant radiotherapy (RT) after radical prostatectomy did not improve outcomes in prostate cancer as compared with salvage ...

Adjuvant pembrolizumab had an estimated 91.2% overall survival rate after 4 years compared with 86.0% for patients with clear ...

Two agents have been approved by the Food and Drug Administration (FDA) for adjuvant use after nephrectomy on the basis of a disease-free survival benefit observed in randomized, placebo ...

The global agricultural adjuvant market is forecast to expand at 6% CAGR over the forecast period, as per FMI’s analysis. The ...

On 18 April 2024, the US Food and Drug Administration (FDA) approved Roche’s Alecensa (alectinib), an oral anaplastic ...

Adjuvant pembrolizumab therapy after surgery for renal-cell carcinoma was approved on the basis of a significant improvement in disease-free survival in the KEYNOTE-564 trial. Whether the results ...

Zoom in a little further and it’s evident that an innovative variation on the VMAT theme – known as tangential VMAT (tVMAT) – is similarly established as the go-to treatment modality for adjuvant ...

Recently published article reports the findings of a randomized clinical trial that investigated the impact of ultrasound-guided quadratus lumborum block (QLB) on analgesia and ...

Welcome to the Moderna's first-quarter 2024 conference call. [Operator instructions] Please be advised, today's conference is ...

The approval was based on data from the phase 3 ALINA trial. The US Food and Drug Administration (FDA) has approved Alecensa (alectinib) as adjuvant treatment for adults with ALK-positive non-small ...

The US Food and Drug Administration (FDA) has approved alectinib (Alecensa, Genentech) in the adjuvant setting following ...